0000950170-23-071250.txt : 20231218 0000950170-23-071250.hdr.sgml : 20231218 20231218204912 ACCESSION NUMBER: 0000950170-23-071250 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231214 FILED AS OF DATE: 20231218 DATE AS OF CHANGE: 20231218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yale Catriona CENTRAL INDEX KEY: 0001779308 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 231495386 MAIL ADDRESS: STREET 1: C/O AKERO THERAPEUTICS INC. STREET 2: 170 HARBOR WAY 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2023-12-14 0001744659 Akero Therapeutics, Inc. AKRO 0001779308 Yale Catriona C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 false true false false Chief Development Officer false Common Stock 2023-12-14 4 S false 597 20.76 D 77910 D Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. /s/ Jonathan Young, Attorney-in-Fact 2023-12-18